Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

OssDsign: Sales are spinning in the spine market - ABG

OSSDThird party research21.08.2024, 07.30

This is a third party research report and does not necessarily reflect our views or values

Download report (PDF)
Solid sales but slightly higher opex
EBIT revised down by 4.1-8.5% for '24e-'26e
Fair value revised down to SEK 8-14 (8-15)


Second quarter as a pure play US orthobiologics company

OssDsign released a rather stable set of numbers for Q2 with sales of SEK 29.7m (0% vs ABGSCe at SEK 29.7m) and EBIT of SEK -15.3m (-9% vs ABGSCe of SEK -14.0m). The lower-than-expected EBIT was due to higher variable sales costs, including higher commissions and higher administrative expenses. On a positive note, the gross margin was slightly better than expected, but the company highlights that this may fluctuate in the coming quarters. Q2 was now the second quarter in which OssDsign is only selling its orthobiologics product, Catalyst, in one market, the US. Q2 sales of SEK 29.7m represented 139% y-o-y comparable growth, adjusted for the discontinued business and currency. Sequentially, total Q2 sales grew 10%.